Literature DB >> 34102952

Familial exudative vitreoretinopathy with TGFBR2 mutation without signs of Loeys-Dietz syndrome.

Toshiaki Asano1, Kazuma Oku1, Hiroyuki Kondo1.   

Abstract

Background: Familial exudative vitreoretinopathy (FEVR) is an inherited retinal disorder with high genetic heterogeneity, and it is characterized by a defect in the development of the retinal vascular system. Loeys-Dietz syndrome (LDS) is an autosomal dominant systemic connective tissue disorder that is caused by mutations in the genes related to transforming growth factor signaling systems including the TGFBR2 gene. Two earlier studies reported that patients with LDS from mutations in the TGFBR2 gene were associated with FEVR-like retinal phenotype. The purpose of this study was to determine the characteristics of a case of FEVR without systemic abnormalities who had a mutation in the TGFBR2 gene.Materials and
Methods: The clinical appearances and surgical outcomes were determined from the medical records. Genetic analysis was performed by whole exome sequencing.
Results: A 15-year-old boy was diagnosed with FEVR by the appearance of the peripheral retina of both eyes and a retinal detachment in the left eye. Whole exome sequencing revealed a heterozygous deletion mutation in the TGFBR2 gene. A de novo mutation was confirmed by examining the family members. No systemic abnormalities were detected in the patient including those associated with LDS.Conclusions: FEVR can be associated with a TGFBR2 mutation without showing signs of LDS.

Entities:  

Keywords:  FEVR; Familial exudative vitreoretinopathy; Loeys-Dietz syndrome; TGFBR2

Mesh:

Substances:

Year:  2021        PMID: 34102952     DOI: 10.1080/13816810.2021.1938137

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  1 in total

1.  A novel frameshift variant in the TSPAN12 gene causes autosomal dominant FEVR.

Authors:  Li Peng; Erkuan Dai; Haodong Xiao; Rulian Zhao; Yunqi He; Shujin Li; Mu Yang; Zhenglin Yang; Peiquan Zhao
Journal:  Mol Genet Genomic Med       Date:  2022-04-13       Impact factor: 2.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.